Skip to content

Registry for Patients Receiving Intravenous Nutrition at Home

Home Total Parenteral Nutrition (HTPN) in Canada: A New Website Based Patient Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02299466
Acronym
HTPN
Enrollment
1000
Registered
2014-11-24
Start date
2005-12-31
Completion date
2029-12-31
Last updated
2022-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parenteral Nutrition, Home

Keywords

parenteral nutrition, complications, indications, long-term administration, HTPN

Brief summary

The purpose of study is to build a Canadian HTPN Registry to collect pertinent demographic and clinical data on the HTPN population in Canada and to determine the factors affecting survival, complications and TPN-dependency. These results will help establish standards of practice and develop future multi-center studies. This will greatly benefit the HTPN patient population.

Detailed description

The HTPN Registry is website based. Only users inside of Canada will be able to access the website. All data is held in Ontario, Canada and is governed by Ontario and Canadian privacy and security laws. The entry point into the registry will be through a website www.htpnregistry.ca, using a specific HTPN program password for data entry. A code and date of birth will be used to identify each patient. Patient data will be kept confidential and be entered by a member of the TPN team from each participating program. Participating programs will have access to their own database and will be able to compare their patient population to the one of the entire registry. Data entered into the registry will include: 1) Patient demography 2) Nutritional assessment 3) Medications 4) Indications for HTPN 5) Gastrointestinal anatomy following surgeries 6) HTPN regimen 7) Current blood work 8) Vascular access 9) Hospitalizations 10) Survival, 11) Liver complications 12) Metabolic bone disease 13) quality of life. In addition, information regarding each HTPN program will be captured: organization of the TPN team, number of patients under the program, diagnosis and reasons for HTPN, source of funding, geographical coverage, home care utilization, providers. Data will be entered every two years by the one or more HTPN staff monitoring the patients. The data can be entered directly into the website or case report forms can be used to collect the data from the patient charts and facilitate data input into the website. All patients will be followed prospectively until discontinuation of TPN or death. Descriptive statistics will be performed. For the entire HTPN population, probability of survival, chronic cholestasis, complicated home parenteral nutrition related liver disease, line infection and metabolic bone disease will be calculated using the Kaplan-Meier method. As of February 2014, 433 patients (85 from UHN) have been entered into the Canadian HTPN registry. The recruitment and data collection is expected to continue for at least 5 more years (until 2019). Participating HTPN programs are: Toronto (Toronto General Hospital, St. Michael's Hospital), Hamilton (Hamilton Health Sciences),Winnipeg (St. Boniface General Hospital), Edmonton (Capital Health/University Of Alberta), Calgary (Foothills Medical Centre), British Columbia (BC Home Parenteral Nutrition Program) and Montreal (McGill University).

Interventions

None listed

Sponsors

Canadian Nutrition Society
CollaboratorOTHER
Baxter Healthcare Corporation
CollaboratorINDUSTRY
Ontario Medical Supply
CollaboratorUNKNOWN
University Health Network, Toronto
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with long-term administration of home total parenteral nutrition Age \>18 years

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Nutritional statusbi-annually up to 10 years, discontinuation of HTPN or deathBody weight, body mass index

Secondary

MeasureTime frameDescription
Medicationsbi-annually up to 10 years, discontinuation of HTPN or deathImmunosuppressors, motility agents, antidiarrheal, sedatives, antidepressors, anticoagulants, insulin, inhibitors of acid secretion, medication to treat liver disease (eg. urso, carnitine, choline…), medication to treat metabolic bone disease (eg. iv/oral calcium, vitamin D, biphosphonate, calcitonin,… are collected from the charts
Indications for HTPNbi-annually up to 10 years, discontinuation of HTPN or deathShort bowel, motility disorder, cancer, surgical complications, pancreatic disorders, other causes of malabsorption
Gastrointestinal anatomybi-annually up to 10 years, discontinuation of HTPN or deathAnatomy as described in medical records
HTPN regimenbi-annually up to 10 years, discontinuation of HTPN or deathEnergy, amino acids, lipids, fluid, electrolytes, vitamins, trace elements
Current blood workbi-annually up to 10 years, discontinuation of HTPN or deathComplete blood count , biochemistry including liver enzymes, total protein, albumin, prealbumin, vit B12, red blood cell folate, iron studies,international normalized ratio /prothrombin time /partial thromboplastin time , cholesterol, triglycerides, trace elements;parathyroid hormone , 24-hr urine oxalate
Patient characteristicsbaselineAge, sex, medical history
Hospitalizationsbi-annually up to 10 years, discontinuation of HTPN or deathNumber/year and TPN related or not TPN related
Survivalbi-annually up to 10 years, discontinuation of HTPN or deathAlive, death: causes, TPN-related or not TPN-related
Liver complicationsbi-annually up to 10 years, discontinuation of HTPN or deathDiagnosis, abdominal ultrasound results, liver biopsy results
Metabolic Bone Diseasebi-annually up to 10 years, discontinuation of HTPN or deathBone mineral density results, fracture risk and reported fractures
Quality of life based on Karnofsky performance scalebi-annually up to 10 years, discontinuation of HTPN or deathKarnofsky performance scale (0-100 point scale)
Vascular accessbi-annually up to 10 years, discontinuation of HTPN or deathtype of catheter, number of lumens, changes in vascular access, complications (line sepsis, occlusion)

Countries

Canada

Contacts

Primary ContactJohane Allard, MD,FRCPC
johane.allard@uhn.on.ca416-340-5159
Backup ContactKatherine JP Schwenger, BASc, MAN, RD, PhD
kschweng@uhnresearch.ca+1-416-340-4413

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026